Key result
Novel w/o nano-emulsion adjuvant induces humoral and cell-mediated immune responses versus commercial ISA-206.
Why the study?
A stable and bio-compatible w/o nano-emulsion adjuvant for foot and mouth disease vaccine was developed to improve immune response compared with existing adjuvants.
A novel w/o nano-emulsion adjuvant demonstrated the ability to induce both humoral and cell-mediated immune responses for foot and mouth disease vaccines.
May advance FMD vaccine formulation; leaves open immunogenicity and field efficacy trials.
A stable and bio-compatible w/o nano-emulsion was developed as adjuvant for foot and mouth disease (FMD) vaccine with isopropyl myristate as oil phase, polyglycerol polyricinoleate, and Tween 80 as surfactants. Dissolving Tween 80 in aqueous phase decreased the droplet size and improved stability of the emulsion through narrowing size distribution, increasing viscosity, and reducing the interfacial tension between oil and water. The nano-emulsion was then formulated with inactivated FMD virus and ovalbumin to investigate its potential application as an adjuvant. Compared with commercial ISA-206 adjuvant, the novel w/o nano-emulsion was able to induce both humoral- and cell-mediated immune response.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2016) studied Foot and mouth disease (FMD) vaccine development. w/o nano-emulsion adjuvant vs. commercial ISA-206 adjuvant was evaluated on humoral- and cell-mediated immune response. A novel w/o nano-emulsion adjuvant formulated with inactivated FMD virus induced both humoral- and cell-mediated immune responses compared with commercial ISA-206 adjuvant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: